BioTechX US 2025

We’re excited to sponsor BioTechX US and highlight our collaboration with Bristol Myers Squibb (BMS). At the conference, Anna Kondic, Vice President of Pharmacometrics, Translational Medicine, and Clinical Pharmacology at BMS, will present alongside Matteo Marano, Director and Global Portfolio Leader at Certara, on the broad impact of mechanistic modeling in improving patient care. 

Visit our booth to meet Certara experts and explore how solutions like BaseCase, D360, Simcyp, QSP, and Model-Based Meta-Analysis (MBMA) empower pharma and biotech teams to communicate value, unify and analyze data, simulate drug behavior and disease biology, and integrate evidence across studies to optimize development, dosing, and regulatory decisions. 

Date: Tuesday, September 16 

Time: 2:50pm 

Poster Title: Derisking Decision Making by Incorporating Early Economic Evaluation for Pharmaceutical Assets 

This presentation will highlight how integrating quantitative approaches—such as pharmacometrics and model-based meta-analysis—with health economics early in drug development can optimize both clinical and economic outcomes, illustrated through three case studies that underscore the importance of cross-functional collaboration, clearly defined model assumptions, and conducting evaluations prior to Phase 3. 

Anna Georgieva Kondic, Vice President of Pharmacometrics, Translational Medicine, and Clinical Pharmacology, BMS 

Dr. Anna Kondic currently heads the Pharmacometrics group at BMS; this group includes mechanistic modeling and clinical pharmacometrics, data science and noncompartmental analysis and has dedicated efforts to create workflow in ML/AI.  Anna has worked as a quantitative scientist in various therapeutic areas and companies over the last 25 years and has extensive experience in both mechanistic and empirical model development across the whole spectrum of R&D, as well as reimbursement. She holds a PhD in mathematics from Duke University and MBA from Stern School of Business at New York University. Anna is particularly passionate about the use of quantitative methods to make personalized medicine a reality, especially for cancer patients.  

Anna is a competitive master artistic swimmer, participating in both national and international meets. She is particularly proud of having been the captain for the Merck Rhode Island team for Swim Across America in 2018. The charity swim that year raised more than 700 000 for cancer research at the Women and Infants Hospital in Providence, RI. 

Craig Comisar, Senior Director of Pharmacometrics

With over 16 years in the field, Craig brings a deep expertise in modeling & simulation, helping streamline drug development across diverse therapeutic areas—including oncology, immunology, and cardiovascular diseases. His journey began with a PhD in chemical engineering, where he specialized in reaction kinetics, later transitioning to pharmacometrics to tackle the complexities of drug behavior in patients.

He joined Certara (formerly Quantitative Solutions) in the spring of 2013. He spent a majority of his career as a pharmacometrician at Janssen [formerly Centocor] and worked in the area of modeling biologic entities for regulatory submissions including exploratory and confirmatory analyses along with dosing guidance simulations. His work covers areas including pediatric indications, immunology, neuroscience, oncology and anti-infectives. Dr. Craig Comisar received his chemical engineering PhD from University of Michigan under Dr. Phillip Savage in reaction kinetics in 2007, after which he obtained a pharmacometrics postdoctoral fellowship at Children’s Hospital of Philadelphia under Dr. Jeffery Barrett. Aside from his modeling/simulation activities, Craig enjoys painting, contrabass clarinet, and German board games with his family. He also enjoys a good game of soccer, basketball, Ultimate Frisbee or any other pickup game that he can find.